NeuroScientific locks in key US FDA meeting
AI Summary
NeuroScientific has scheduled an important meeting with the US FDA regarding its StemSmart technology designed for treating refractory Crohn’s disease, with plans for a Phase 2 clinical trial. This development highlights progress in biopharmaceutical treatments targeting serious health conditions.
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
Health NeuroScientific FDA meeting StemSmart Crohn's disease Phase 2 trial biopharma medical technology